← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Treace John T.
Chief Executive Officer | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001856380
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 6
- Purchases · 24M
- 7
- Average purchase
- $282.1K
- Median purchase
- $246.8K
- Gross purchase value
- $2.0M
Companies: TREACE MEDICAL CONCEPTS, INC.
7 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-24 | TREACE MEDICAL CONCEPTS, INC. | TMCI | Chief Executive Officer | Officer | $246.8K | Open filing |
| 2026-06-12 | TREACE MEDICAL CONCEPTS, INC. | TMCI | Chief Executive Officer | Officer | $99.1K | Open filing |
| 2026-06-11 | TREACE MEDICAL CONCEPTS, INC. | TMCI | Chief Executive Officer | Officer | $210.8K | Open filing |
| 2026-06-01 | TREACE MEDICAL CONCEPTS, INC. | TMCI | Chief Executive Officer | Officer | $178.0K | Open filing |
| 2026-05-28 | TREACE MEDICAL CONCEPTS, INC. | TMCI | Chief Executive Officer | Officer | $340.4K | Open filing |
| 2026-05-14 | TREACE MEDICAL CONCEPTS, INC. | TMCI | Chief Executive Officer | Officer | $375.7K | Open filing |
| 2025-03-04 | TREACE MEDICAL CONCEPTS, INC. | TMCI | Chief Executive Officer | Officer | $523.8K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/6
- Large purchase ≥ $100k
- 6/7
- Cluster buying · 15D
- 0/7
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.